BF Biosciences Limited ne announce kiya hai ke company ne apna naya product Zeptide (Tirzepatide) Pakistan mein successfully launch kar diya hai, jo ek easy-to-use pre-filled syringe format mein available hai.
Tirzepatide aik synthetic polypeptide molecule hai jo GLP-1 aur GIP receptors dono par kaam karta hai — yani yeh aik dual agonist hai jo glucose aur insulin dono ke natural mechanisms ko target karta hai. Yeh drug US FDA se Type 2 Diabetes Mellitus (T2DM) aur obesity ke ilaaj ke liye approved hai.
Zeptide ko BF Biosciences ke state-of-the-art European prefilled syringes facility mein manufacture kiya gaya hai. Is ka patient-friendly design dosing errors se bachata hai. Product ko US ki leading biological mass spectrometry facility aur Pakistan ke aik national university mein test kiya gaya, jahan uski quality, chemical structure, aur potency verify ki gayi.
Yeh project IPO proceeds utilization plan ka hissa tha.
Pakistan duniya mein diabetes ke sabse zyada cases walay mulkon mein se aik hai — taqriban 9 million log aise hain jinhain diabetes hai magar ab tak diagnose nahi hui, jab ke jinhein pata hai wo bhi management mein mushkilat ka samna karte hain. WHO ke mutabiq, 57% Pakistani women aur 41% men overweight ya obese hain, aur obesity Type 2 diabetes ka risk 7 guna barhati hai.
Pakistan ke pehle Biopharmaceutical Plant ke taur par, BF Biosciences Limited pechlay aik das saal se HCV, Cancer, Cardiology, Diabetes, Nephrology aur dusre therapeutic areas ke liye essential medicines banata aa raha hai.
Company ka kehna hai ke Zeptide ka launch na sirf BF Biosciences ki growth ko boost karega balkay unke mission ko bhi mazboot karega — “critical unmet patient needs” ko address karne ke liye.
